Mesenchymal stem cell-secreted soluble signaling molecules potentiate tumor growth

Cell Cycle

Volumn 10, Issue 18, 2011, Pages 3198-3207

  Zhu, Wei ^a   Huang, Ling ^a   Li, Yahong ^a   Qian, Hui ^a   Shan, Xiuhong ^a   Yan, Yongmin ^a   Mao, Fei ^a   Wu, Xiaosheng ^b   Xu, Wen Rong ^a  

^a JIANGSU UNIVERSITY   (China)

^b MAYO CLINIC   (United States)

Author keywords

Angiogenesis; Mechanism; Mesenchymal stem cell; Reprogramming; Soluble signaling molecules; Tumor associated fibroblast; Tumor growth

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE; CELL ISOLATION; CELL PROLIFERATION; CHEMICAL ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PROTEIN EXPRESSION; TUMOR GROWTH;

EID: 80052904128     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.18.17638     Document Type: Article

References (40)

1. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102:3837-44; PMID:12881305; DOI:10.1182/blood- 2003-04-1193.
2. Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F, 3rd. Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells 2011; 29:11-9; PMID:21280155; DOI:10.1002/stem.559.
3. Kucerova L, Matuskova M, Hlubinova K, Altanerova V, Altaner C. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol Cancer 2010; 9:129; PMID:20509882; DOI:10.1186/1476-4598-9-129.
4. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011; 71:614-24; PMID:21224357; DOI:10.1158/0008-5472.CAN-10-0538.
5. Roorda BD, ter Elst A, Kamps WA, de Bont ES. Bone marrow-derived cells and tumor growth: contribution of bone marrow-derived cells to tumor micro-environments with special focus on mesenchymal stem cells. Crit Rev Oncol Hematol 2009; 69:187-98; PMID:18675551; DOI:10.1016/j.critrevonc.2008.06.004.
6. Brune JC, Tormin A, Johansson MC, Rissler P, Brosjo O, Lofvenberg R, et al. Mesenchymal stromal cells from primary osteosarcoma are non-malignant and strikingly similar to their bone marrow counterparts. Int J Cancer 2011; 129:319-30; PMID:20878957; DOI:10.1002/ijc.25697.
7. Kunz-Schughart LA, Knuechel R. Tumor-associated fibroblasts (part I): Active stromal participants in tumor development and progression? Histol Histopathol 2002; 17:599-621; PMID:11962761.
8. Kunz-Schughart LA, Knuechel R. Tumor-associated fibroblasts (part II): Functional impact on tumor tissue. Histol Histopathol 2002; 17:623-37; PMID:11962762.
9. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE 2009; 4:4992; PMID:19352430; DOI:10.1371/journal.pone.0004992.
10. Hung SC, Deng WP, Yang WK, Liu RS, Lee CC, Su TC, et al. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin Cancer Res 2005; 11:7749-56; PMID:16278396; DOI:10.1158/1078-0432.CCR-05-0876.
11. Ishii G, Sangai T, Oda T, Aoyagi Y, Hasebe T, Kanomata N, et al. Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochem Biophys Res Commun 2003; 309:232-40; PMID:12943687; DOI:10.1016/S0006-291X(03)01544-4.
12. Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, Ganesan S, et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 2008; 68:4331-9; PMID:18519693; DOI:10.1158/0008-5472.CAN-08- 0943.
13. Galiè M, Konstantinidou G, Peroni D, Scambi I, Marchini C, Lisi V, et al. Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice. Oncogene 2008; 27:2542-51; PMID:17998939; DOI:10.1038/sj.onc.1210920.
14. Prantl L, Muehlberg F, Navone NM, Song YH, Vykoukal J, Logothetis CJ, et al. Adipose tissue-derived stem cells promote prostate tumor growth. Prostate 2010; 70:1709-15; PMID:20564322; DOI:10.1002/pros.21206.
15. Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Kodama M, Higashi Y, et al. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer 2010; 127:2323-33; PMID:20473928; DOI:10.1002/ijc.25440.
16. Yu JM, Jun ES, Bae YC, Jung JS. Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells Dev 2008; 17:463-73; PMID:18522494; DOI:10.1089/scd.2007.0181.
17. Zhu W, Xu W, Jiang R, Qian H, Chen M, Hu J, et al. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 2006; 80:267-74; PMID:16214129; DOI:10.1016/j.yexmp.2005.07.004.
18. Gonzalez-Moreno O, Lecanda J, Green JE, Segura V, Catena R, Serrano D, et al. VEGF elicits epithelialmesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop. Exp Cell Res 2010; 316:554-67; PMID:20006606; DOI:10.1016/j.yexcr.2009.11.020.
19. Littlepage LE, Egeblad M, Werb Z. Coevolution of cancer and stromal cellular responses. Cancer Cell 2005; 7:499-500; PMID:15950897; DOI:10.1016/j.ccr.2005.05.019.
20. Chiavarina B, Whitaker-Menezes D, Migneco G, Martinez-Outschoorn UE, Pavlides S, Howell A, et al. HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartmentspecific oncogenesis. Cell Cycle 2010; 9:3534-51; PMID:20864819; DOI:10.4161/cc.9.17.12908
21. Lewis DA, Travers JB, Machado C, Somani AK, Spandau DF. Reversing the aging stromal phenotype prevents carcinoma initiation. Aging (Albany NY) 2011; 3:407-16; PMID:21515933.
22. Pavlides S, Tsirigos A, Migneco G, Whitaker-Menezes D, Chiavarina B, Flomenberg N, et al. The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle 2010; 9:3485-505; PMID:20861672; DOI:10.4161/cc.9.17.12721.
23. Pavlides S, Tsirigos A, Vera I, Flomenberg N, Frank PG, Casimiro MC, et al. Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: similarities with oxidative stress, inflammation, Alzheimer's disease and "Neuron-Glia Metabolic Coupling". Aging (Albany NY) 2010; 2:185-99; PMID:20442453.
24. Klopp AH, Lacerda L, Gupta A, Debeb BG, Solley T, Li L, et al. Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS ONE 2010; 5:12180; PMID:20808935; DOI:10.1371/journal.pone.0012180.
25. Martin FT, Dwyer RM, Kelly J, Khan S, Murphy JM, Curran C, et al. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res Treat 2010; 124:317-26; PMID:20087650; DOI:10.1007/s10549-010- 0734-1.
26. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 2006; 203:1235-47; PMID:16636132; DOI:10.1084/jem.20051921
27. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006; 5:755-66; PMID:16546991; DOI:10.1158/1535-7163.MCT-05-0334
28. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005; 65:3307-18; PMID:15833864.
29. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004; 11:1155-64; PMID:15141157; DOI:10.1038/sj.gt. 3302276.
30. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004; 96:1593-603; PMID:15523088; DOI:10.1093/jnci/djh299.
31. Grum-Schwensen B, Klingelhofer J, Berg CH, El-Naaman C, Grigorian M, Lukanidin E, et al. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res 2005; 65:3772-80; PMID:15867373; DOI:10.1158/0008-5472.CAN-04-4510.
32. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121:335-48; PMID:15882617; DOI:10.1016/j.cell.2005.02.034.
33. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449:557-63; PMID:17914389; DOI:10.1038/nature06188.
34. Weber JD, Raben DM, Phillips PJ, Baldassare JJ. Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem J 1997; 326:61-8; PMID:9337851.
35. Balmanno K, Cook SJ. Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 1999; 18:3085-97; PMID:10340380; DOI:10.1038/sj.onc.1202647.
36. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7; PMID:12490959; DOI:10.1038/nature01322.
37. Xu W, Zhang X, Qian H, Zhu W, Sun X, Hu J, et al. Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp Biol Med (Maywood) 2004; 229:623-31; PMID:15229356.
38. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 2006; 103:1475-9; PMID:16432179; DOI:10.1073/pnas.0510857103.
39. Mangieri D, Nico B, Coluccia AM, Vacca A, Ponzoni M, Ribatti D. An alternative in vivo system for testing angiogenic potential of human neuroblastoma cells. Cancer Lett 2009; 277:199-204; PMID:19150583; DOI:10.1016/j.canlet.2008.12.014.
40. Chen Y, Wang Y, Yu H, Wang F, Xu W. The cross talk between protein kinase A- and RhoA-mediated signaling in cancer cells. Exp Biol Med (Maywood) 2005; 230:731-41; PMID:16246900.